Prothena Corporation plc (PRTA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRTA Revenue Growth
Revenue Breakdown (FY 2025)
PRTA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PRTA Revenue Analysis (2014–2025)
As of May 8, 2026, Prothena Corporation plc (PRTA) generated trailing twelve-month (TTM) revenue of $57.9 million, reflecting explosive growth of +1706.4% year-over-year. The most recent quarter (Q1 2026) recorded $51.1 million in revenue, up 243157.1% sequentially.
Looking at the longer-term picture, PRTA's 5-year compound annual growth rate (CAGR) stands at +62.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $200.6 million in 2021.
Revenue diversification analysis shows PRTA's business is primarily driven by Collaboration (99%), and License (1%). With over half of revenue concentrated in Collaboration, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FOLD (+20.0% YoY), RARE (+13.3% YoY), and IONS (+47.5% YoY), PRTA has outperformed the peer group in terms of revenue growth. Compare PRTA vs FOLD →
PRTA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRTACurrent | $58M | +1706.4% | +62.6% | -1905.8% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% |
PRTA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $9.7M | -92.8% | $6.0M | 61.8% | $-184,560,000 | -1905.8% |
| 2024 | $135.2M | +47.9% | $135.2M | 100.0% | $-154,561,000 | -114.4% |
| 2023 | $91.4M | +69.5% | $91.4M | 100.0% | $-191,036,000 | -209.1% |
| 2022 | $53.9M | -73.1% | $53.9M | 100.0% | $-131,557,000 | -244.1% |
| 2021 | $200.6M | +23414.3% | $200.6M | 100.0% | $72.0M | 35.9% |
| 2020 | $853K | +4.8% | $-74,031,000 | -8678.9% | $-112,734,000 | -13216.2% |
| 2019 | $814K | -14.8% | $-50,022,000 | -6145.2% | $-85,697,000 | -10527.9% |
| 2018 | $955K | -96.5% | $-100,228,000 | -10495.1% | $-158,855,000 | -16634.0% |
| 2017 | $27.5M | +2508.4% | $-107,028,000 | -388.9% | $-155,254,000 | -564.2% |
| 2016 | $1.1M | -34.3% | $-118,479,000 | -11230.2% | $-159,535,000 | -15121.8% |
See PRTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRTA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRTA — Frequently Asked Questions
Quick answers to the most common questions about buying PRTA stock.
Is PRTA's revenue growth accelerating or slowing?
PRTA revenue is accelerating at +1706.4% year-over-year, exceeding the 5-year CAGR of +62.6%. TTM revenue reached $58M. Growth momentum has increased versus prior periods.
What is PRTA's long-term revenue growth rate?
Prothena Corporation plc's 5-year revenue CAGR of +62.6% reflects the sustained expansion pattern. Current YoY growth of +1706.4% is above this long-term average.
How is PRTA's revenue distributed by segment?
PRTA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.